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Abstract: Background: We aim to understand whether all patients with hormonal receptor (HR)-positive
(+)/human epidermal growth factor receptor-2 (HER2)-negative (−) metastatic breast cancer (MBC)
should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a first-line approach.
Methods: A network meta-analysis (NMA) using the Bayesian hierarchical arm-based model, which
provides the estimates for various effect sizes, were computed. Results: First-line treatment options
in HR+/HER2− MBC, including CDK 4/6 inhibitors combined with aromatase inhibitors (AIs) or
fulvestrant (F), showed a significantly longer progression-free survival (PFS) in comparison with
AI monotherapy, with a total of 26% progression risk reduction. In the indirect comparison across
the three classes of CDK 4/6 inhibitors and F endocrine-based therapies, the first strategy resulted
in longer PFS, regardless of specific CDK 4/6 inhibitor (HR: 0.68; 95% CrI: 0.53–0.87 for palbociclib
+ AI, HR: 0.65; 95% CrI: 0.53–0.79 for ribociclib + AI, HR: 0.63; 95% CrI: 0.47–0.86 for abemaciclib
+ AI) and patient’s characteristics. Longer PFS was also found in patients with bone-only and soft
tissues limited disease treated with CDK 4/6 inhibitors. Conclusions: CDK 4/6 inhibitors have similar
efficacy when associated with an AI in the first-line treatment of HR+ MBC, and are superior to either
F or AI monotherapy, regardless of any other patients or tumor characteristics.
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1. Introduction
Hormone receptor (HR)-positive (+) and human epidermal growth factor receptor type
(HER2)-negative (−) metastatic breast cancer (MBC) represents the most common invasive cancer
subtype in women [1]. Almost two-thirds of women with newly diagnosed MBC have HR+ tumors,
and approximately 25% of women with an early HR+ breast cancer diagnosis eventually relapse after
adjuvant treatments [2].
As the role of estrogens in etiology and breast cancer progression is well-established, the
modification of estrogen activity has represented the treatment of choice in women with HR+ MBC
for several years, particularly for those with slowly progressive disease and limited tumor-related
symptoms [3]. Selective estrogen receptor modulators (such as tamoxifen) [4], selective estrogen receptor
down-regulators (SERDs, like fulvestrant [F]) [5,6] aromatase inhibitors (AIs; such asletrozole [7],
anastrazole [8] or exemestane [9]) are the mainstay of anticancer endocrine therapy (ET) [10]. The
recent addition of CDK 4/6 inhibitors to standard ET has further improved outcomes in both first- and
later-line therapy settings. CDK 4/6 inhibitors act by inactivating the complex CDK-D-type cyclins
(CCND), leading to an increase in the retinoblastoma protein (pRb), which negatively regulates E2F
transcriptional factors, eventually resulting in the inhibition of cell cycle progression and apoptosis of
tumor cells [11].
In the first-line setting, CDK 4/6 inhibitors, which mechanistically work in different ways through
estrogen receptor interference, have been studied in combination with AIs in the PALOMA-2 [12],
MONALEESA-2 [13], and MONARCH-3 studies in the context of postmenopausal women [14], as well
as in premenopausal women, in combination with either tamoxifen or an AI in the MONALEESA-7
study [15]. In particular, palbociclib, ribociclib, and abemaciclib, the three available CDK 4/6 inhibitors,
in combination with standard ET, showed progression-free survival (PFS) improvement in phase III
trials, and have been approved for use in first and in later lines of therapy in women with HR+HER2−
MBC, regardless of menopausal status, age, endocrine sensitivity and type of metastasis [12,16].
Interestingly, although the mechanism of action of these CDK 4/6 inhibitors is similar, they also present
some differences. In fact, while palbociclib and ribociclib have a similar chemical structure, abemaciclib
is 14-times more potent against CDK 4 compared with CDK 6 and presents a higher selectivity for the
complex CDK 4/cyclin D1 [11].
Despite the progress made in efficacy, combination therapy also resulted in increased toxicities,
costs, and tighter clinical monitoring for patients [17]. In addition, the improvement in PFS has not yet
translated into an increase in overall survival (OS) for all studies focusing on first-line settings [18–20].
Therefore, how and when to incorporate CDK 4/6 inhibitors in the complex management of HR+
HER2−MBC remains one of the main unmet clinical need in this setting [21].
Indeed, single-agent ET yielded a median PFS ranging from 14 to 16 months in the control arms
of the first-line trials with CDK 4/6 inhibitors. Thus, the fact that for some patients, the addition of
CDK 4/6 inhibitors might be avoided is a debated clinical topic. Moreover, according to the Fulvestrant
and Anastrozole Compared in Hormonal Therapy Naive Advanced Breast Cancer (FALCON) trial,
comparing F with anastrozole in the same setting, the single-agent F therapy may be a further reasonable
option for HR+/HER2−MBC patients who are ET-naïve, especially those with the non-visceral disease.
Indeed, the median PFS of 16.6 months reported in the F arm compared with 13.3 months in the
anastrozole arm, which was observed in the context of the general population, was even higher in
patients without visceral disease (22.3 versus 13.6 months; hazard ratio [HR]: 0.59; 95% CI: 0.42–0.84) [5].
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The ongoing studies, which are evaluating predictive markers of endocrine resistance or sensitivity,
will probably provide enough evidence for helping in the clinical decision-making and for a better
definition of the optimal ET-based strategy for this specific set of luminal breast cancer [22–24].
In the meantime, in our current daily clinical practice, also considering minor or uncertain
differences in efficacy between the available CDK 4/6 inhibitors, the choice of first-line ET strategy is
essentially based on one of the three CDK 4/6 inhibitors according to their specific toxicity profile and
patient comorbidities or preferences.
Considering the lack of formal and reliable comparisons between the three CDK 4/6 inhibitors,
in addition to the lower toxicity profile of F, the aim of this systematic review and meta-analysis is the
indirect comparison between the combination strategy, including CDK 4/6 inhibitors plus AI [12–15],
and F-based therapies for the first-line treatment of HR+/HER2−MBC [5,25–27].
2. Materials and Methods
2.1. Search Strategy and Study Selection
We followed the PRISMA statement for reporting systematic reviews and meta-analysis. Two
authors independently examined the abstracts retrieved by a search strategy in electronic databases
(MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials) from November 2011 to
June 2019. We used the following search string ((metastatic breast cancer) AND (CDK 4/6 inhibitor OR
endocrine therapy OR aromatase inhibitor OR letrozole OR anastrozole OR exemestane OR tamoxifen
OR F OR palbociclib OR everolimus OR ribociclib OR abemaciclib). The research was conducted on
5 June 2019. Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting, San
Antonio Breast Cancer Annual Symposium, and the European Society of Medical Oncology Annual
Meeting were also queried from November 2011 to June 2019 for relevant abstracts. In cases where a
report of the same trial was obtained, the most recent results were included (corresponding to longer
follow-up). Then, the authors examined full-text articles of potentially eligible studies according to
the eligibility criteria. Disagreements on the inclusion of selected trials were resolved in discussions
with another author. This article does not contain any studies with human participants or animals
performed by any of the authors. It was unnecessary, given the study does not contain any studies
with human participants or animals performed by any of the authors.
2.2. Eligibility Criteria
We decided only to include phase III randomized controlled trials (RCTs) that reported the
comparison of CDK 4/6 inhibitors plus ET or F plus or less ET versus ET treatment alone as first-line
treatment in HR+/HER2−MBC. We also excluded trials with incomplete data or different control arm.
2.3. Outcomes
The primary outcome was PFS, calculated from the date of randomization to the date of progression
(defined by the Response Evaluation Criteria in Solid Tumors “RECIST” 1.1 criteria or death). The
secondary outcomes were: (1) objective response rate (ORR): defined as the percentage of patients
with complete or partial response as per RECIST 1.1 criteria (as assessed in all randomly assigned
patients); (2) clinical benefit (CB): defined as a confirmed complete or partial response or stable disease
lasting 24 weeks or more; (3) OS: defined as the time from randomization to death from any causes.
Subgroup meta-regression analysis was also conducted for PFS indirect comparison according to age,
Eastern Cooperative Oncology Group (ECOG) performance status, ethnicity, prior chemotherapy or
ET exposure, measurable disease at the time of metastasis occurrence, visceral or bone-only disease,
time from the initial diagnosis of breast cancer to metastasis onset.
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2.4. Data Collection and Statistical Analysis
A network meta-analysis (NMA) was carried out utilizing the method in the study by
Valkenhoef et al. [28], which performed NMA using the Bayesian hierarchical arm-based model
and provides estimates for various effect sizes. For PFS, HR and 95% credible interval (CrI) were
reported. In addition, ORR and CB rates were reported, and the results were expressed as odds ratios
(OR) with their 95% CrI. The NMA plot, in which treatments directly compared were connected with
straight line was generated. NMAs on patients’ subgroups were also performed. All analyses were
performed using R Statistical Software version 3.4.3 along with the gemtc package, which uses Markov
chain Monte Carlo (MCMC) techniques through Just Another Gibbs Sampler (JAGS) [29].
3. Results
3.1. Study Selection
Through the search strategy, we identified four phase III trials comparing 1441 patients
treated with CDK 4/6 inhibitors (palbociclib, ribociclibor, abemaciclib) in combination with an AI
(1106 patients) [12–14], an AI plus ovarian function suppression (OFS; 248 premenopausal patients),
or tamoxifen plus OFS (87 premenopausal patients) [15]. Three other phase III randomized controlled
trials (RCTs) compared 837 patients treated with F alone (230 patients) or in combination with AI
(607 patients) versus a total of 1891 patients treated with AI alone (letrozole 2.5 mg daily or anastrozole
1 mg per day on a continuous schedule), tamoxifen plus OFS (90 premenopausal patients) or AI
plus OFS (247 premenopausal) [5,25,27]. The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram for study inclusion is shown in Figure 1.
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3.2. Description of Studies and Patients
Table 1 summarizes the main characteristics and outcomes of each trial. Palbociclib and ribociclib
were tested in combination with letrozole 2.5 mg/day in PALOMA-2 and MONALEESA-2, respectively.
Abemaciclib was used in combination with anastrozole 1 mg/day (19.9%) or letrozole 2.5 mg/day
(79.1%) as per the physician’s choice in the MONARCH-3 trial. Furthermore, ribociclib was also
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studied in premenopausal patients in the context of the MONALEESA-7 trial. Specifically, in this
study, ribociclib was combined with tamoxifen plus goserelin (26%) or with letrozole 2.5 mg/day or
anastrozole 1 mg/day plus goserelin (74%). Eventually, F alone or in combination with anastrozole
1 mg/day was compared with the AI in the FALCON, Southwest Oncology Group (SWOG), and
Fulvestrant and Anastrozole Combination Therapy (FACT) trials. The primary outcome was PFS in all
trials (Table 1); secondary outcomes (ORR, CB rate, OS) in all trials were also reported in Table 1, while
the NMA core design is shown in Figure 2. The network plot in Figure 2 offers a visual representation of
the evidence. Nodes represent treatments, and edges represent the available direct comparisons—that
is, they connect treatments that are directly compared in studies.
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Table 1. Main characteristics and outcomes of the seven eligible trials included for meta-analysis.
Study and First
Author
Publication
Year Phase Setting Post-Menopausal RR (%) CB (%)
Median PFS
(months)
Median OS
(months)
PALOMA-2
Finn [12] 2016 III
First-line therapy for MBC in patients not
treated before for their metastatic disease. Yes 42.1 vs. 34.7 84.9 vs. 70.3 24.8 vs. 14.5 NR
MONALEESA-2
Hotobagyi [13]
2016
2018 III
First-line therapy for locally advanced and
MBC. Patients who had not received previous
systemic therapy for advanced disease were
eligible. Previous neoadjuvant or adjuvant
therapy with a nonsteroidal AI was not
allowed unless the disease-free interval was
more than 12 months
Yes 40.7 vs. 27.542.5 vs. 28.7
79.6 vs. 72.8
79.9 vs. 73.1
NR vs. 14.7
25.3 vs. 16
NR
NR vs. 33
MONARCH-3
Goetz [14] 2017 III
First-line therapy for locally advanced and
MBC (endocrine therapy in the neoadjuvant
or adjuvant setting was permitted if the
patient had a disease-free interval 12 months
from the completion of endocrine therapy)
Yes 48.2 vs. 34.5 78 vs. 71.5 NR vs. 14.7 NR
MONALEESA-7
Tripathy [15]
2018
2019 III
First-line therapy for locally advanced or
MBC (endocrine therapy and chemotherapy
in the adjuvant or neoadjuvant setting was
permitted, as was up to one line of
chemotherapy for advanced disease).
Not (only pre and
perimenopausal
women were included
and treated with
goserelin)
41 vs. 30 79 vs. 70 23.8 vs. 13.0 NRNR vs. 40.9
FALCON
Robertson [5] 2016 III
First-line therapy for locally advanced or
MBC (no previous adjuvant therapy was
admitted, only a first-line CHT for metastatic
disease was accepted)
Yes 46 vs. 45 78 vs. 74 16.6 vs. 13.8 NR
SWOG
Mehta [26]
2012
2019 III
First line for de novo MBC or recurrent MBC
after 12 months by the end of adjuvant CHT
or HT
Yes 27 vs. 22 73 vs. 70 15 vs. 13.515 vs. 13.5
47.7 vs. 41.3
49.8 vs. 42
FACT
Bergh [27] 2012 III
First-line therapy in recurrent MBC after or
during primary treatment (with or without
HT, CHT, RT). Patients treated with an
adjuvant AI had to be relapse-free for more
than one year after completion of this type of
endocrine therapy (30.2% of the patients in
the experimental arm were endocrine naive)
Yes (only 3% of patients
wer in the
premenopausal status
and were treated with
GnRH agonists)
31.8 vs. 33.6 55 vs. 55.1 10.8 vs. 10.2 37.8 vs. 38.2
AI: aromatase inhibitor; CB: clinical benefit; CHT: chemotherapy; HT: hormonal therapy; MBC: metastatic breast cancer; GnRH, gonadotropin-releasing hormone; NR: not reported; OS:
overall survival; PFS: progression-free survival; RR: response rate; RT: radiotherapy.
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3.3. Outcomes
3.3.1. Progression-Free Survival
As shown in the indirect comparison between CDK 4/6 inhibitors versus F-based therapies, the
first strategy resulted in longer PFS, regardless of the specific CDK 4/6 inhibitor (HR: 0.68; 95% CrI:
0.53–0.87 for palbociclib + AI, HR: 0.65; 95% CrI: 0.53–0.79 for ribociclib + AI, HR: 0.63; 95% CrI:
0.47–0.86 for abemaciclib + AI) (Figure 3; top)
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3.3.2. Objective Response
The CDK 4/6 inhibitors combination strategies resulted in higher RR in indirect comparison with
F (OR:1.3; 95% CrI: 0.81–2.0 from palbociclib + AI versus AI: OR:1.6; 95% CrI: 1.1–2.5 from ribociclib +
AI versus AI: OR:1.6; 95% CrI: 1.1–2.4 from abemaciclib + AI versus AI). (Figure 3; middle)
3.3.3. Clinical Benefit
The CDK 4/6 inhibitor combination strategies resulted in higher CB in indirect comparison with F
(OR: 2.1; 95% CrI: 1.3–3.3 from palbociclib + AI versus AI: OR: 1.3; 95% CrI: 0.92–1.8 from ribociclib +
AI versus AI: OR:1.2; 95% CrI: 0.81–1.8 from abemaciclib + AI versus AI). (Figure 3; bottom).
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3.3.4. Overall Survival
For overall survival (OS), no indirect comparison by NMA was performed because not all
the studies data were completely mature. Indeed, data on OS have been recently reported in the
MONALEESE-7 study where the estimated OS at 42 months was 70.2% (95% CI 63.5–76.0) in the CDK
4/6 inhibitor arm versus 46% (95% CI: 32–58.9) in the ET alone arm [18,19] In addition, also the SWOG
trial has recently shown the median OS of 49.8 months in 71% of the patients receiving F combination
strategy vs. 42 months in 76% of the patients receiving ET monotherapy alone [23].
3.3.5. Safety Profile
The main adverse effects registered in each trial are reported in Table 2.
Table 2. Main adverse effects registered in each trial.
Study Treatment AEs G3 (%) G4 (%)
PALOMA-2
Palbociclib–letrozole
Any AEs 62.2% 13.5%
Neutropenia 56.1% 10.4%
Leukopenia 24.1% 0.7%
Placebo–letrozole
Any AEs 22.1% 2.3%
Neutropenia 0.9% 0.5%
MONALEESA-2
Ribociclib–letrozole
Neutropenia 52.4% 9.6%
Abnormal LFT 8.4% 1.8%
Leukopenia 20.1% 1.2%
Placebo–letrozole
Abnormal LFT 2.4% –
Neutropenia, anemia,
arthralgia 1.2% –
MONARCH-3
Abemaciclib–nonsteroidal AI
Any AEs 51.7% 6.7%
Neutropenia 22.0% 1.8%
Leukopenia 8.3% 0.3%
ALT increase 6.1% 0.3%
Placebo–nonsteroidal AI
Any AEs 22.4% 2.5%
Neutropenia 0.6% 0.6%
MONALEESA-7
Ribociclib group
Any AEs 63% 14%
Neutropenia 51% 10%
Leukopenia 13% 1%
Placebo group Any AEs 26% 4%
Neutropenia 3% 1%
FALCON
Robertson
Fulvestrant
Arthralgia (17%)
Hot flush, fatigue, nausea (11%)
Back pain (9%)
Anastrozole Arthralgia, hot flush, nausea (10%)
SWOG
Mehta
Anastrozole
Musculoskeletal pain,
fatigue, hot flashes, mood
alterations, GI symptoms
15% (each 1–4%)
Anastrozole–fulvestrant
Musculoskeletal pain,
fatigue, hot flashes, mood
alterations, GI symptoms
13% (each 1–4%)
FACT
Bergh
Anastrozole
GI symptoms (25.2%)
Joint disorders (27.6%)
Hot flashes (13.8%)
Anastrozole–fulvestrant
GI symptoms (28.9%)
Joint disorders (26.6%)
Hot flashes (24.6%)
ALT: alanine aminotransferase; AE: adverse event; AI: aromatase inhibitor; GI: gastrointestinal; G3: grade 3; G4:
grade 4; LFT: liver function test.
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3.4. Subgroup Analyses
Table 3 summarizes the main patient’s characteristic according to subgroups analysis in each trial.
Subgroup NMA among the three classes of CDK 4/6 inhibitors and F is reported in Figure 4.
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NMA results also suggested a different potential tropism among them, which should be further
investigated in prospective clinical trials.
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Table 3. Main characteristics of the patients included in the randomized trials evaluated for the present network meta-analysis.
Characteristics
PALOMA-2, n (%) MONALEESA-2, n(%)
MONARCH-3, n
(%) MONALEESA-7, n (%) FALCON
a, n (%) SWOG b, n (%) FACT4, n (%)
L. +
Palb. L.
L. +
Rib. L.
L or A.
+ Abem. L. or A.
Rib. + T or
nAIs
T or
nAIs F. A. F.+ A. A. F. + A. A.
No. of patients 444 222 334 334 328 165 335 337 230 232 345 349 258 256
Age:
• Median (range), years 62(3089) 61(28–88)
62
(23–91)
63
(29–88)
63
(38–87)
63
(32–88) 43 (25–58)
45
(29–58)
64
(38–87)
62
(36–90)
65
(36–91)
65
(27–92)
65
(33–86)
63
(36–90)
• <65 years 263(59.2)
141
(63.5) NR NR NR NR NR NR NR NR NR NR
124
(48.1)
145
(56.6)
• ≥65 years 181(40.8) 81 (36.5) NR NR NR NR NR NR 108 (47) 91 (39) NR NR
134
(51.9)
111
(43.3)
Ethnicity:
• White 344(77.5)
172
(77.5)
269
(80.5)
280
(83.8)
186
(56.7)
102
(61.8) 187 (56) 201 (60) 175 (76) 174 (75) NR NR
242
(93.8)
237
(92.6)
• Asian 65 (14.6) 30 (13.5) 28 (8.4) 23 (6.9) 103(31.4) 45 (27.3) 99 (30) 99 (29) 36 (16) 34 (15) NR NR 4 (1.6) 2 (0.8)
• Black 8 (1.8) 3 (1.4) 10 (3.0) 7 (2.1) NR NR 10 (3) 9 (3) NR NR NR NR 1 (0.4) 2 (0.8)
• Other 27 (6.1) 17 (7.7) 27 (8.1) 24 (7.2) 11 (3.4) 7 (4.2) 39 (12) 28 (8) 19 (8) 24 (10) NR NR 11 (4.3) 15 (5.9)
Hormone receptor status:
• ER+, PgR+ NR NR NR NR 255(77.7)
127
(77.0) 290 (87) 288 (85) 175 (76) 179 (77) NR NR
193
(74.8)
195
(76.2)
• ER+, PgR− NR NR NR NR 70 (21.3) 36 (21.8) NR NR 44 (19) 43 (19) NR NR 60 (23.3) 51 (19.9)
• Unknown NR NR NR NR NR NR NR NR 10(4) 7 (3) NR NR 4 (1.6) 6 (2.3)
• ER−PgR+ NR NR NR NR NR NR NR NR 1 (<1) 3 (1) NR NR 1 (0.4) 4 (1.6)
Performance status:
• ECOG 0 257(57.9)
102
(45.9)
205
(61.4)
202
(60.5)
192
(58.5)
104
(63.0) 245 (73) 255 (76) 117 (51) 115 (50) NR NR NR NR
• ECOG 1 178(40.1)
117
(52.7)
129
(38.6)
132
(39.5)
136
(41.5) 61 (37.0) 87 (26) 78 (23) 106 (46) 105 (45) NR NR NR NR
• ECOG 2 9 (2.0) 3 (1.4) NR NR NR NR 0 1 (<1) 7 (3) 12 (5) NR NR NR NR
• ECOG > 2 NR NR NR NR NR NR NR NR NR NR NR NR NR NR
• Unavailable NR NR NR NR NR NR 3 (1) 3 (1) NR NR NR NR NR NR
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Table 3. Cont.
Characteristics
PALOMA-2, n (%) MONALEESA-2, n(%)
MONARCH-3, n
(%) MONALEESA-7, n (%) FALCON
a, n (%) SWOG b, n (%) FACT4, n (%)
L. +
Palb. L.
L. +
Rib. L.
L or A.
+ Abem. L. or A.
Rib. + T or
nAIs
T or
nAIs F. A. F.+ A. A. F. + A. A.
Disease stage:
• I 51 (11.5) 30 (13.5) NR NR NR NR NR NR NR NR NR NR NR NR
• II 137(30.9) 68 (30.6) NR NR NR NR NR NR NR NR NR NR NR NR
• III 72 (16.2) 39 (17.6) 1 (0.3) 3 (0.9) NR NR NR NR NR NR NR NR NR NR
• IV 138(31.1) 72 (32.4)
333
(99.7)
331
(99.1) NR NR NR NR 202 (88) 200 (86) NR NR 245 (95)
242
(94.5)
• Unknown 36 (8.1) 1 (0.5) NR NR NR NR NR NR NR NR NR NR NR NR
Site of metastasis:
• Bone only 103(23.2) 48 (21.6) 69 (20.1) 78 (23.4) 70 (21.3) 39 (23.6) 81 (24) 78 (23) 24 (10) 24 (10) 76 (22.0) 75 (21.5) 63 (24.4) 71 (27.7)
• Visceral 214(48.2)
110
(49.5)
197
(59.0)
196
(58.7)
172
(52.4) 89 (53.9) 193 (58) 188 (56) 135 (59) 119 (51)
167
(48.4)
181
(51.9)
134
(51.9)
124
(48.4)
• Non- visceral 230(51.8)
112
(50.5) NR NR NR NR NR NR 60 (26) 81 (35)
102
(29.6) 93 (26.6)
195
(28.1) NR
• Lymph nodes NR NR 133(39.8)
123
(36.8) NR NR 142 (42) 158 (47) NR NR NR NR NR NR
• Other NR NR 45 (12.9) 33 (9.9) 86 (26.2) 37 (22.4) 8 (2) 8(2) 11 (4) 8 (4) NR NR 1 (0.4) 1 (0.4)
Measurable disease:
• Yes NR NR NR NR 267(81.4)
130
(78.8) NR NR 193 (84) 196 (84)
188
(54.5)
188
(53.9)
129
(50.0)
113
(44.1)
• No NR NR NR NR 61 (18.6) 35 (21.2) NR NR NR NR 157(45.5)
161
(46.1)
129
(50.0)
143
(55.9)
Disease-free interval:
• De novo 167(37.6) 81 (36.5)
114
(34.1)
113
(33.8) NR NR 136 (41) 134 (40) NR NR NR NR NR NR
• ≤12 months 99 (22.3) 48 (21.6) 4 (1.2) 10 (3.0) NR NR 23 (7) 13 (4) NR NR NR NR 14 (5.4) 18 (7.0)
• >12 months 178(40.1) 93 (41.9)
216
(64.7)
210
(62.9) NR NR 176 (53) 190 (56) NR NR NR NR 85 (32.9) 78 (30.5)
• Unknown NR NR NR 1 (0.3) NR NR NR NR NR NR NR NR NR NR
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Table 3. Cont.
Characteristics
PALOMA-2, n (%) MONALEESA-2, n(%)
MONARCH-3, n
(%) MONALEESA-7, n (%) FALCON
a, n (%) SWOG b, n (%) FACT4, n (%)
L. +
Palb. L.
L. +
Rib. L.
L or A.
+ Abem. L. or A.
Rib. + T or
nAIs
T or
nAIs F. A. F.+ A. A. F. + A. A.
No. of disease sites
• 0 NR NR 2 (0.6) 1 (0.3) NR NR 1 (<1) NR NR NR NR NR NR NR
• 1 138(31.1) 66 (29.7)
100
(29.9)
117
(35.0) 96 (29.3) 47 (28.5) 112 (33) 117 (35) NR NR NR NR NR NR
• 2 117(26.4) 52 (23.4)
118
(35.3)
103
(30.8) 76 (23.2) 42 (25.5) 106 (32) 99 (29) NR NR NR NR NR NR
• 3 112(25.2) 61 (27.5)
114
(34.1)
113
(33.8) 154 (47)
2 75
(45.5)2 116 (35) 121 (36) NR NR NR NR NR NR
• ≥4 77 (17.3) 43 (19.4) NR NR NR NR NR NR NR NR NR NR NR NR
Prior chemotherapy:
• Adjuvant 180(40.5) 89 (40.1)
146
(43.7)
145
(43.4)
125
(38.1) 66 (40.0) 138 (41) 138 (41) 35 (15) 27 (12)
103
(29.9)
129
(37.0)
108
(41.9)
127
(49.6)
• Neoadjuvant 54 (12.2) 32 (14.4) * * * * * * 11 (5) 16 (7) NR NR NR NR
• Palliative NR NR NR NR NR NR 47 (14) 47 (14) 36 (16) 43 (19) NR NR NR NR
• None NR NR NR NR 203(61.9) 99 (60.0) 150 (45) 152 (45) NR NR
242
(70.1)
220
(63.0) NR NR
Prior hormonal therapy:
• Adjuvant 249(56.1)
126
(56.8)
175
(52.4)
171
(51.2)
150
(45.7) 80 (48.5) 127 (38) 141 (42) 2 (1) 1 (<1)
139
(40.3)
141
(40.4)
180
(69.8)
168
(65.6)
• Neoadjuvant NR * *
• None NR NR NR NR 178(54.3) 85 (51.5) 208 (62) 196 (58) NR NR
206
(59.7)
208
(59.6) NR NR
Type of adjuvant ET:
• Tamoxifen 209(47.1) 98 (44.1)
140
(41.9)
145
(43.4) NR NR NR NR NR NR NR NR NR NR
• Anastrozole 56 (12.6) 29 (13.1) 47 (14.1) 42 (12.6) NR NR NR NR NR NR NR NR NR NR
• Letrozole 36 (8.1) 16 (7.2) 34 (10.2) 25 (7.5) NR NR NR NR NR NR NR NR NR NR
• Exemestane 30 (6.8) 13 (5.9) 19 (5.7) 25 (7.5) NR NR NR NR NR NR NR NR NR NR
• Other NR NR 8 (2.4) 7 (2.1) NR NR NR NR NR NR NR NR NR NR
a The experimental arm consisted of F 500 mg intramuscular injection; on days 0, 14, 28, then every 28 days thereafter. b The experimental arm consisted of F 500 mg on day 1 and 250 mg
on days 14 and 28 and monthly thereafter. * Patients included among those of the adjuvant setting. L: letrozole; Palb.: palbociclib; Rib: Ribociclib; A: anastrozole; Abe: abemaciclib; T:
tamoxifen; nAIs: non-steroidal aromatase inhibitors; F: fulvestrant; NR: not reported; ECOG: Eastern Cooperative Oncology Group; ER: estrogen receptor; PgR: progesteron receptor;
+: positive.
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4. Discussion
HR+/HER2− BC is the most common subtype of this disease, representing approximately 60–70%
of all breast tumors [1]. For many years, the sequential use of ET was the preferred approach in HR+
MBC patients due to its effectiveness and favorable toxicity profile [3,30,31]. The recent introduction
of new combinations of ET plus CDK 4/6 or phosphatidylinositol 3-kinases (PI3K) inhibitors led to
further clinical improvement in HR+ MBC patients [30,31]. Regarding the first-line setting, several
randomized phase III clinical trials clearly demonstrated that the three highly selective CDK 4/6
inhibitors (palbociclib, ribociclib, abemaciclib) significantly improve ORR and CB and prolong PFS
when combined with an AI or tamoxifen, both in pre- and post-menopausal women [12–15].
Although clinical outcomes are very similar for the three CDK 4/6 inhibitors and are not influenced
by classic clinical and pathological factors, several differences were recognized concerning their toxicity
profile and mechanism of action. In the patients who received the combination CDK 4/6 inhibitor plus
ET, a higher incidence of hematologic adverse events occurred compared to control groups. The most
common hematologic adverse events with grade 3 or 4 were neutropenia (43% vs. 1%), leucopenia
(20% vs. 0.4%), anemia (5% vs. 1%), and thrombocytopenia (2% vs. 0.1%) [32]. Despite the high
incidence of neutropenia reported in the RCTs, a higher incidence of febrile neutropenia was not
recorded, which is evident just in 1.3% of patients. Unlike palbociclib and ribociclib, abemaciclib caused
low-grade diarrhea and transaminase elevation, readily managed with conventional medications
or dose reduction [17]. On the other hand, data suggest that abemaciclib has distinct single-agent
activity at the molecular level, which could reflect its unique effects and toxicity profile [33]. For
example, abemaciclib, but not ribociclib or pabociclib, is a potent inhibitor of kinases other than CDK
4/6, including CDK1/cyclin B, which appears to cause arrest in the G2 phase of the cell cycle, and
CDK2/cyclin E/A, which is implicated in resistance to palbociclib. Whereas ribociclib and palbociclib
induce cytostasis, and cells adapt to these drugs within 2–3 days of exposure, abemaciclib induces cell
death and durably blocks cell proliferation. Abemaciclib is active even in pRB-deficient cells in which
CDK 4/6 inhibition by palbociclib or ribociclib is completely ineffective [34]. In luminal tumors, some
useful biomarkers are being studied to identify the best target treatment combined with anti-hormonal
therapy and which can then determine the ideal choice for activity rather than toxicity. Recently, the
PI3K mutation presented in progressive luminal tumors from the first-line treatment with AI showed a
significant benefit in PFS when associated with F [35].
Against this background, knowing whether these three agents can be interchangeable remains an
urgent unmet clinical need [21,32,36,37]. Thus, a better understanding of molecular differences is a
relevant challenge since it could be informative for their right use in the clinical setting. Additionally,
since there are no comparative data between CDK 4/6 inhibitors and F, the hormonal agent approved
in endocrine-naïve patients with MBC for first-line setting, the identification of the most suitable
HR+ MBC patients who can benefit most from the less toxic F-based-therapy is still a significant
challenge [5,21]. Herein, we performed a meta-analysis, including only data from phase III RCTs
available concerning the same clinical scenario. This approach allows the synthesis of a large body of
evidence while retaining the benefits of randomization within each trial. Hence, we use this indirect
comparison method to investigate whether F-based ET could still play a role in some specific subgroup
of patients with HR+ MBC in the first-line setting
In this meta-analysis, we found that CDK 4/6 inhibitors produced significant improvement in
ORR, CB, and PFS in all patients with HR+ MBC in comparison with F-based therapies. Furthermore,
these results were independent of age, race, performance status, disease site, prior chemotherapy, prior
ET, disease-free interval after adjuvant treatment, menopausal status, type of CDK 4/6 inhibitor or
expression of the progesterone receptor. Interestingly, significant PFS improvement in favor of CDK
4/6 inhibitors was observed even in patients with bone-only disease and in non-visceral disease. Due
to the lack of convincing efficacy criteria to prefer one or the other CDK 4/6 inhibitor, the choice should
rely on the toxicity profile. It must be remembered, however, that no direct comparison has ever been
performed between the three CDK 4/6 inhibitors to allow an appropriate selection in the clinic.
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Our meta-analysis has several limitations suggesting caution in interpreting the results. First, it is
not based on individual patient data but was conducted considering the HR and 95% CIs of each study
extracted. Moreover, for some subgroups, the HRs were not reported in all studies, particularly in
F-based trials. In addition, the number of trials was relatively limited, preventing formal comparisons
among all treatment strategies for each group. Second, and this is a well-known caveat of studies with
F, not all the included studies with this compound used the now considered standard dose (500 mg
monthly plus an additional dose of 500 mg for 15 days during the first month) [25,27]. The CONFIRM
trial has revealed a superior activity of 500 mg when compared with 250 mg of F in terms of PFS and
OS [6]. Therefore, the non-standard F dose used in some trials may partially bias our findings. Third,
while the four RCTs [12–15] including CDK 4/6 inhibitors are rather homogenous in terms of inclusions
criteria and patient characteristics, the greater heterogeneity observed in F-based studies [5,25,27]
inevitably affected the pooled meta-analyses results. For instance, the line of therapy, metastatic sites,
tumor burden, prior anti-estrogen drugs, and anti-estrogen treatment sequence, previous endocrine
therapies sensitivity were also heterogeneous. Notably, F was more effective in endocrine-naïve
patients without the visceral disease [5]. As demonstrated in Table 1, the FALCON trial exclusively
included those patients who had never been exposed to ET, both in the metastatic and early settings.
By contrast, a percentage ranging from 40 to 65% of patients included in the remaining trials were
previously exposed to ET in the adjuvant or neoadjuvant settings. In addition, F efficacy in “bone-only”
limited disease was not established in all studies [27]. Finally, for peri and premenopausal patients, we
cannot rule out the possibility that the administered luteinizing hormone-releasing hormone analog
(LHRHa) may affect the final estimation, as LHRHa itself was reported as an effective endocrine
approach in breast cancer. Moreover, the limited number of peri or premenopausal patients in F-based
studies makes a comparison between F and CDK 4/6 inhibitor ET strategies unreliable in this setting of
patients. Specifically, while the FALCON and SWOG trials were enrolled merely post-menopausal
patients, in the FACT trial, premenopausal patients were also included and were treated with GnRHa.
Unfortunately, they only represented 3.1% of the experimental arm. Although previous reviews and
meta-analyses of treatments in MBC patients have been conducted, many of these studies focus on
population different from the current study. For example, Ayyagari et al. explored the safety and
efficacy of only two CDK 4/6 inhibitors (palbociclib and ribociclib) in postmenopausal women after
progression on a non-steroidal AI [35]. Ding et al. also conducted a similar NMA, focusing on the
results of all three CDK4/6 inhibitors in phase II and III trials both in the first and second lines; however,
the analysis did not include a direct comparison with F in first-line treatment [32]. Finally, El Rassy et al.
investigated which CDK4/6 inhibitor was more effective in patients with luminal breast cancer, but their
study was limited by the small sample size and lack of studies on F (1 included) [36]. Therefore, our
study specifically focused on the results of phase III studies in the first-line setting and comprised an
indirect comparison with first-line F. In addition, the present meta-analysis includes recently published
data that were not included in previous reviews, in particular, the results of MONALEESA-7 on
premenopausal women [32,36,37]. Despite the differences in study design and specific limitations, the
results of our and previous NMAs are consistent in reporting the improved clinical outcomes obtained
with CDK4/6 inhibitors compared with monotherapy [32,36,37].
5. Conclusions
In conclusion, the results of this meta-analysis confirm that CDK 4/6 inhibitors have similar
efficacy when associated with an AI in the first-line treatment of HR+ MBC, and are superior to either
F or AI monotherapy, regardless of any other patients or tumor characteristics. Though all CDK 4/6
inhibitors resulted associated with similar outcomes, the differences in toxicity profile, drug interactions,
and patient preferences seem to be the main factors to be considered in the clinical decision-making
process. Interestingly, CDK 4/6 inhibitors with AI resulted in more effective than F-based therapies
even in patients with the bone-limited disease and, what is more, in patients without visceral disease
involvement. Hence, the use of F in the first-line setting is destined to be abandoned as a single agent,
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and its right place in HR+ MBC patients management needs to be urgently refined. Based on preclinical
and early clinical trial results, its mechanism of action and pharmacokinetic properties make it an
ideal backbone for combination therapies contributing to overcome or delaying endocrine resistance.
Rational combinations with other therapies, such as PI3K inhibitors, HER2-directed therapies, and
immunotherapy, are being explored. The emerging data also suggest a potential use of CDK4/6-targeted
approaches in neoadjuvant settings (Supplementary Table S1). Different clinical trials are also ongoing
to assess the safety and efficacy of CDK4/6 inhibitors alone or in combination with chemotherapy in
different groups of patients. These trials, together with future comparative studies and biomarker
analyses, are indispensable to better select patients who derive the greatest benefit from a specific class
of CDK 4/6 inhibitors.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/11/1661/s1,
Table S1: The most important phase II or III ongoing clinical trials investigating CDK 4/6 inhibitors in breast cancer.
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